Exact Sciences Discloses Shareholder Lawsuits Challenging Abbott Merger, Provides Supplemental Proxy Details
EXAS has more than doubled off its 52-week low of $38.812 on light trading volume (0.4× avg).
Summary
Exact Sciences has filed additional proxy materials in response to shareholder lawsuits challenging its proposed acquisition by Abbott Laboratories, providing supplemental disclosures to its definitive proxy statement.
Key Events · Legal and Risk Events · EXAS
-
Shareholder Lawsuits Filed
Three lawsuits have been initiated by purported stockholders in New York State court, alleging deficiencies in the definitive proxy statement related to the Abbott merger.
-
Voluntary Supplemental Disclosures
Exact Sciences is providing additional disclosures to address the lawsuits, aiming to avoid delays or adverse effects on the merger, without admitting liability.
-
Updated Financial Analysis
The supplemental disclosures include revisions to the Discounted Cash Flow, Selected Public Company, and Selected Precedent Transactions analyses performed by Centerview Partners.
-
Revised Financial Projections
Certain financial projections, including Adjusted EBITDA and Unlevered Free Cash Flow, have been updated due to a licensing agreement expense.
Analysis · EXAS · Industrial Applications And Services
This filing is highly important as it reveals that the proposed acquisition of Exact Sciences by Abbott Laboratories is facing legal challenges from shareholders. Three lawsuits have been initiated, alleging misleading information or omitted material details in the definitive proxy statement. While Exact Sciences believes these claims are without merit, it has voluntarily provided supplemental disclosures to mitigate litigation risks and prevent potential delays to the merger. These disclosures include updated financial analysis from Centerview Partners and revised financial projections, which are crucial for shareholders evaluating the fairness of the $105.00 per share cash offer. The presence of these lawsuits introduces uncertainty and potential delays to the merger timeline.
At the time of this filing, EXAS was trading at $103.35 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $19.7B. The 52-week trading range was $38.81 to $103.54. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.